Page 22 - Read Online

Page 14 of 15 Miura et al. Vessel Plus 2019;3:1 I http://dx.doi.org/10.20517/2574-1209.2018.69

Imaging and Prevention, Society for Cardiovascular Angiography and Interventions, Society of Interventional Radiology, Society of
NeuroInterventional Surgery, Society for Vascular Medicine, and Society for Vascular Surgery. Circulation 2011;124:e54-130.
67. Smilde TJ, van Wissen S, Wollersheim H, Trip MD, Kastelein JJ, et al. Effect of aggressive versus conventional lipid lowering
on atherosclerosis progression in familial hypercholesterolaemia (ASAP): a prospective, randomised, doubleblind trial. Lancet
2001;357:577-81.
68. Corti R, Fuster V, Fayad ZA, Worthley SG, Helft G, et al. Effects of aggressive versus conventional lipid-lowering by simvastatin on
human atherosclerotic lesions: a prospective, randomized, double-blind trial with high-resolution magnetic resonance imaging. J Am
Coll Cardiol 2005;46:106-12.
69. Underhill HR, Yuan C, Zhao XQ, Kraiss LW, Parker DL, et al. Effect of rosuvastatin therapy on carotid plaque morphology
and composition in moderately hypercholesterolemic patients: a high-resolution magnetic resonance imaging trial. Am Heart J
2008;155:584.
70. Lee JM, Wiesmann F, Shirodaria C, Leeson P, Petersen SE, et al. Early changes in arterial structure and function following statin
initiation: quantification by magnetic resonance imaging. Atherosclerosis 2008;197:951-8.
71. Lenglet S, Quercioli A, Fabre M, Galan K, Pelli G, et al. Statin treatment is associated with reduction in serum levels of receptor
activator of NF-kB ligand and neutrophil activation in patients with severe carotid stenosis. Mediators Inflamm 2014;2014:720987.
72. McGirt MJ, Perler BA, Brooke BS, Woodworth GF, Coon A, et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors reduce
the risk of perioperative stroke and mortality after carotid endarterectomy. J Vasc Surg 2005;42:829-36.
73. Tanemura H, Maeda M, Ichikawa N, Miura Y, Umeda Y, et al. High-risk plaque for carotid artery stenting evaluated with 3-dimensional
T1-weighted gradient echo sequence. Stroke 2013;44:105-10.
74. Texakalidis P, Giannopoulos S, Jonnalagadda AK, Chitale RV, Jabbour P, et al. Preoperative use of statins in carotid artery stenting: a
systematic review and meta-analysis. J Endovasc Ther 2018;25:624-31.
75. De Caterina R, Scarano M, Marfisi R, Lucisano G, Palma F, et al. Cholesterol-lowering interventions and stroke: insights from a meta-
analysis of randomized controlled trials. J Am Coll of Cardiol 2010;55:198-211.
76. Sorrentino SA, Besler C, Rohrer L, Meyer M, Heinrich K, et al. Endothelial-vasoprotective effects of high-density lipoprotein are
impaired in patients with type 2 diabetes mellitus but are improved after extended-release niacin therapy. Circulation 2010;121:110-22.
77. Villines TC, Stanek EJ, Devine PJ, Turco M, Miller M, et al. The ARBITER 6-HALTS trial (arterial biology for the investigation of
the treatment effects of reducing cholesterol 6-HDL and LDL treatment strategies in atherosclerosis): final results and the impact of
medication adherence, dose, and treatment duration. J Am Coll Cardiol 2010;55:2721-6.
78. Lavigne PM, Karas RH. The current state of niacin in cardiovascular disease prevention: a systematic review and meta-regression. J Am
Coll Cardiol 2013;61:440-6.
79. Bloomfield Rubins H, Davenport J, Babikian V, Brass LM, Collins D, et al. Reduction in stroke with gemfibrozil in men with coronary
heart disease and low HDL cholesterol: the veterans affairs HDL intervention trial (VA-HIT). Circulation 2001;103:2828-33.
80. Jun M, Foote C, Lv J, Neal B, Patel A, et al. Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis.
Lancet 2010;375:1875-84.
81. Ishibashi S, Arai H, Yokote K, Araki E, Suganami H, et al. Efficacy and safety of pemafibrate (K-877), a selective peroxisome
proliferator-activated receptor α modulator, in patients with dyslipidemia: results from a 24-week, randomized, double blind, active-
controlled, phase 3 trial. J Clin Lipidol 2018;12:173-84.
82. Calvo MJ, Martínez MS, Torres W, Chávez-Castillo M, Luzardo E, et al. Omega-3 polyunsaturated fatty acids and cardiovascular
health: a molecular view into structure and function. Vessel Plus 2017:1:116-28.
83. Thies F, Garry JM, Yaqoob P, Rerkasem K, Williams J, et al. Association of n-3 polyunsaturated fatty acids with stability of
atherosclerotic plaques: a randomised controlled trial. Lancet 2003;361:477-85.
84. Cawood AL, Ding R, Napper FL, Young RH, Williams JA, et al. Eicosapentaenoic acid (EPA) from highly concentrated n-3 fatty
acid ethyl esters is incorporated into advanced atherosclerotic plaques and higher plaque EPA is associated with decreased plaque
inflammation and increased stability. Atherosclerosis 2010;212:252-9.
85. Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, et al. Ezetimibe added to statin therapy after acute coronary syndromes.
N Engl J Med 2015;372:2387-97.
86. Bohula EA, Wiviott SD, Giugliano RP, Blazing MA, Park JG, et al. Prevention of stroke with the addition of ezetimibe to statin therapy
in patients with acute coronary syndrome in IMPROVE-IT (improved reduction of outcomes: vytorin efficacy international trial).
Circulation 2017;136:2440-50.
87. Barter PJ, Caulfield M, Eriksson M, Grundy SM, Kastelein JJ, et al. Effects of torcetrapib in patients at high risk for coronary events. N
Engl J Med 2007;357:2109-22.
88. Schwartz GG, Olsson AG, Abt M, Ballantyne CM, Barter PJ, et al. Effects of dalcetrapib in patients with a recent acute coronary
syndrome. N Engl J Med 2012;367:2089-99.
89. Lincoff AM, Nicholls SJ, Riesmeyer JS, Barter PJ, Brewer HB, et al. Evacetrapib and cardiovascular outcomes in high-risk vascular
disease. N Engl J Med 2017;376:1933-42.
90. HPS3/TIMI55–REVEAL Collaborative Group, Bowman L, Hopewell JC, Chen F, Wallendszus K, et al. Effects of anacetrapib in
patients with atherosclerotic vascular disease. N Engl J Med 2017;377:1217-27.
91. Dadu RT, Ballantyne CM. Lipid lowering with PCSK9 inhibitors. Nat Rev Cardiol 2014;11:563-75.
92. Navarese EP, Kolodziejczak M, Schulze V, Gurbel PA, Tantry U, et al. Effects of proprotein convertase subtilisin/kexin type 9 antibodies